

## **Title: Current treatment of severe asthma**

### **Biosketch**

Elisabeth Bel is Professor of Medicine and head of Department at the Academic Medical Centre, in Amsterdam, The Netherlands. She qualified in medicine at the University of Amsterdam, and received her PhD training and degree in Respiratory Medicine at Leiden University, The Netherlands. Her research focuses on the more severe types of asthma that are difficult to treat, with a particular emphasis on phenotyping, pathophysiological mechanisms, management and monitoring. She serves on the editorial board of the American Journal of Respiratory and Critical Care Medicine and is active member of the American Thoracic Society and the European Respiratory Society.



### **Key publications**

1. Hashimoto S, Bel EH. Current treatment of severe asthma. 5: Hashimoto S, Bel EH. Current treatment of severe asthma. Clin Exp Allergy. 2012 May;42(5):693-705.
2. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH; on behalf of the members of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66:910-7
3. Van Veen HPAA, ten Brinke A, van der Veen H, Gauw SJ, Sterk PJ, Rabe KF, and Bel EH. Persistent sputum eosinophilia in patients with difficult-to-treat asthma: a 5-year follow-up study,. J Allergy Clin Immunol 2009; 124:615-7.